Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1282135 | 0.83 | KCNA3 (0.50) | DRD2DRD4 | |
| SCHEMBL11022311 | 0.82 | HRH3 (0.49) | KMT2AHRH3KCNH2LMNAMAPK1 | |
| SCHEMBL1282104 | 0.79 | MAPT (0.45) | KMT2AMAPK1SMN1; SMN2MEN1KDM4E | |
| SCHEMBL10360969 | 0.79 | KCNA3 (0.47) | HRH3KCNH2LMNAMAPK1HTT | |
| SCHEMBL6260288 | 0.75 | KDM4E (0.51) | HRH3LMNAMAPK1KDM4EPPARG | |
| SCHEMBL8551026 | 0.75 | KMT2A (0.73) | KMT2AHRH3KCNH2LMNAMAPK1 | |
| SCHEMBL11297445 | 0.74 | HRH3 (0.50) | HRH3LMNAMAPK1KDM4EPPARG | |
| SCHEMBL11296404 | 0.74 | ABCB11 (0.64) | KMT2AHRH3LMNAMAPK1KDM4E | |
| SCHEMBL11022024 | 0.73 | ABCB11 (0.49) | HRH3LMNAMAPK1KDM4EPPARG | |
| SCHEMBL7431046 | 0.73 | ABCB11 (0.49) | HRH3LMNAMAPK1KDM4EPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088660-A1 | Antifungal 1,2,4-triazolyl Derivatives | BASF SE (DE) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088660-A1 | Antifungal 1,2,4-triazolyl Derivatives | ERG28, CYP51A1, DPM1 | KMT2A 3034/4885HRH3 2858/4885KCNH2 2731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.